Lipocine (LPCN)
Develops oral therapies and licenses approved testosterone product TLANDO to commercialization partners.
$2.31
Pre-market−0.08 (−3.35%)
At close$2.39(+3.91%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.32
Revenue estimate
$219.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$0.33−$0.35−$0.41−$0.59−$0.34−$0.54−$0.32Pending
Estimate−$0.40−$0.35−$0.41−$0.56−$0.60−$0.51−$0.40−$0.32
Surprise+182.5%0.0%0.0%−5.4%+43.3%−5.9%+20.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$3.5M$93.9K$622.8K$114.6K$1.1M$1.2M$190.1KPending
Estimate$2.6M$352.0K$238.0K$238.0K$116.0K$162.5K$213.0K$219.0K
Surprise+33.6%−73.3%+161.7%−51.9%+867.8%+634.8%−10.8%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.32 | — | — |
| Aug 2026 | −$0.40 | −$0.32 | +20.0% |
| May 2026 | −$0.51 | −$0.54 | −5.9% |
| Mar 2026 | −$0.60 | −$0.34 | +43.3% |
| Nov 2025 | −$0.56 | −$0.59 | −5.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.32 | — | — | $219.0K | — | — | — |
| Aug 4, 2026 | −$0.40 | −$0.32 | +20.0% | $213.0K | $190.1K | −10.8% | +1.0% |
| May 7, 2026 | −$0.51 | −$0.54 | −5.9% | $162.5K | $1.2M | +634.8% | −0.8% |
| Mar 9, 2026 | −$0.60 | −$0.34 | +43.3% | $116.0K | $1.1M | +867.8% | +2.9% |
| Nov 6, 2025 | −$0.56 | −$0.59 | −5.4% | $238.0K | $114.6K | −51.9% | −3.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 5, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 10, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 9, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 13, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 6, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 7, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 6, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 11, 2015 | |||||||